These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 18205834)

  • 1. Non-hydrolytic functions of acetylcholinesterase. The significance of C-terminal peptides.
    Greenfield SA; Zimmermann M; Bond CE
    FEBS J; 2008 Feb; 275(4):604-11. PubMed ID: 18205834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovering and targeting the basic mechanism of neurodegeneration: the role of peptides from the C-terminus of acetylcholinesterase: non-hydrolytic effects of ache: the actions of peptides derived from the C-terminal and their relevance to neurodegeneration.
    Greenfield S
    Chem Biol Interact; 2013 May; 203(3):543-6. PubMed ID: 23562497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease, Alzheimer's disease and motor neurone disease: identifying a common mechanism.
    Greenfield S; Vaux DJ
    Neuroscience; 2002; 113(3):485-92. PubMed ID: 12150769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A peptide derived from acetylcholinesterase is a pivotal signalling molecule in neurodegeneration.
    Greenfield S
    Chem Biol Interact; 2005 Dec; 157-158():211-8. PubMed ID: 16297900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a technique to identify acetylcholinesterase C-terminal peptides in human serum samples.
    Halliday AC; Kim O; Bond CE; Greenfield SA
    Chem Biol Interact; 2010 Sep; 187(1-3):110-4. PubMed ID: 20156431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First signs of glaucoma injury occur in the brain. What has generally been considered an eye disease is actually related to conditions such as Alzheimer's and Parkinson's diseases.
    Duke Med Health News; 2010 May; 16(5):4-5. PubMed ID: 20518132
    [No Abstract]   [Full Text] [Related]  

  • 7. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides.
    Gallardo G; Schlüter OM; Südhof TC
    Nat Neurosci; 2008 Mar; 11(3):301-8. PubMed ID: 18297066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Caspase activation precedes and leads to neurodegeneration in a murine model of Alzheimer's disease].
    de Calignon A; Spires-Jones TL; Hyman BT
    Med Sci (Paris); 2010 Oct; 26(10):787-9. PubMed ID: 20929661
    [No Abstract]   [Full Text] [Related]  

  • 9. Regional brain evaluation of acetylcholinesterase activity in PS1/A246E transgenic mice.
    Jazi R; Lalonde R; Qian S; Strazielle C
    Neurosci Res; 2009 Feb; 63(2):106-14. PubMed ID: 19056437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo.
    Du Y; Li X; Yang D; Zhang X; Chen S; Huang K; Le W
    Exp Biol Med (Maywood); 2008 Jul; 233(7):881-90. PubMed ID: 18445767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction of the pharmacophore model of acetylcholinesterase inhibitor.
    Zhu Y; Tong XY; Zhao Y; Chen H; Jiang FC
    Yao Xue Xue Bao; 2008 Mar; 43(3):267-76. PubMed ID: 18630262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropathologic changes in the olfactory bulb in Alzheimer's disease.
    Kovács I; Török I; Zombori J; Kása P
    Neurobiology (Bp); 1996; 4(1-2):123-6. PubMed ID: 9116690
    [No Abstract]   [Full Text] [Related]  

  • 13. Non-classical actions of cholinesterases: role in cellular differentiation, tumorigenesis and Alzheimer's disease.
    Greenfield S
    Neurochem Int; 1996; 28(5-6):485-90. PubMed ID: 8792328
    [No Abstract]   [Full Text] [Related]  

  • 14. A modern hypothesis: The distinct pathologies of dementia associated with Parkinson's disease versus Alzheimer's disease.
    Farlow MR; Cummings J
    Dement Geriatr Cogn Disord; 2008; 25(4):301-8. PubMed ID: 18311077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neural degeneration in Parkinson's disease.
    Riederer P; Reichmann H; Janetzky B; Sian J; Lesch KP; Lange KW; Double KL; Nagatsu T; Gerlach M
    Adv Neurol; 2001; 86():125-36. PubMed ID: 11553969
    [No Abstract]   [Full Text] [Related]  

  • 16. Neurovascular signalling defects in neurodegeneration.
    Zacchigna S; Lambrechts D; Carmeliet P
    Nat Rev Neurosci; 2008 Mar; 9(3):169-81. PubMed ID: 18253131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Is leuko-araiosis in Alzheimer's disease, in Parkinson's disease and in healthy elderly persons the result of Wallerian degeneration?].
    Leys D; Pruvo JP; Soetaert G; Vermersch P; Rapoport A; Clarisse J; Petit H
    Acta Neurol Belg; 1989; 89(3-4):249-52. PubMed ID: 2516973
    [No Abstract]   [Full Text] [Related]  

  • 18. Is Alzheimer's disease preceded by neurodegeneration or cerebral hypoperfusion?
    de la Torre JC
    Ann Neurol; 2005 Jun; 57(6):783-4. PubMed ID: 15929049
    [No Abstract]   [Full Text] [Related]  

  • 19. Gait speed in Parkinson disease correlates with cholinergic degeneration.
    Mehanna R
    Neurology; 2014 Apr; 82(17):1568-9. PubMed ID: 24778286
    [No Abstract]   [Full Text] [Related]  

  • 20. Gait speed in Parkinson disease correlates with cholinergic degeneration.
    Landau WM
    Neurology; 2014 Jul; 83(1):102-3. PubMed ID: 24982040
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.